Evidence map›Paper›PMID 40666848›Full record

ArticlebioRxiv : the preprint server for biology2025

Riboflavin drives nucleotide biosynthesis and iron-sulfur metabolism to promote acute myeloid leukemia.

Stefan Bjelosevic, Rahel Fauth, Brian T Do, Gabriela Alexe, Lucy A Merickel, Thomas D Jackson, Allen T Basanthakumar, Audrey Taillon, Silvi Salhotra, Birgitta Ryback and 10 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Stefan BjelosevicDepartment of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.ORCID 0000-0002-3012-9273
Rahel FauthDepartment of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.
Brian T DoKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142 USA.
Gabriela AlexeDepartment of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.
Lucy A MerickelDepartment of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.
Thomas D JacksonDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215 USA.
Allen T BasanthakumarDepartment of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.
Audrey TaillonDepartment of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.
Silvi SalhotraDepartment of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.
Birgitta RybackDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215 USA.
Constanze SchneiderDepartment of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.
Giulia DiGiovanniDepartment of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.
Ryan ElbashirKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142 USA.
Nils BurgerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215 USA.
Muhammad Bin MunimKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142 USA.
Shan LinDepartment of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.
Pere PuigserverDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215 USA.
David E RootBroad Institute of MIT and Harvard, Cambridge, MA, 02142 USA.
Matthew G Vander HeidenKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142 USA.ORCID 0000-0002-6702-4192
Kimberly StegmaierDepartment of Pediatric Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Boston Children's Hospital; Harvard Medical School, Boston, MA, 02215 USA.

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Understanding the role of metabolism in cancerR35CA242379 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VANDER HEIDEN, MATTHEW G. · 2019 to 2025
$5.8M
Targeting Pediatric Cancer VulnerabilitiesR35CA283977 · NCI · DANA-FARBER CANCER INST · PI Kimberly Stegmaier · 2023 to 2026
$4.2M
Characterizing the role of MARCH5 in apoptosis regulation in acute myeloid leukemiaR00CA263161 · NCI · SEATTLE CHILDREN'S HOSPITAL · PI Shan Lin · 2024 to 2026
$747k
Molecular determinants of fetal hemoglobin induction by hydroxyurea to treat sickle cell diseaseF30HL156404 · NHLBI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI DO, BRIAN TSHAO · 2021 to 2023
$155k
NCI NIH HHS P30 CA014051NCI NIH HHS R00 CA263161NCI NIH HHS R35 CA242379NCI NIH HHS R35 CA283977NHLBI NIH HHS F30 HL156404NIGMS NIH HHS T32 GM007753
6 · The paper itself

Abstract

Riboflavin is a diet-derived vitamin in higher organisms that serves as a precursor for flavin mononucleotide and flavin adenine dinucleotide, key cofactors that participate in oxidoreductase reactions. Here, using proteomic, metabolomic and functional genomics approaches, we describe a specific riboflavin dependency in acute myeloid leukemia and demonstrate that, in addition to energy production via oxidative phosphorylation, a key biological role of riboflavin is to enable nucleotide biosynthesis and iron-sulfur cluster metabolism. Genetic perturbation of riboflavin metabolism pathways or exogenous depletion in physiological culture medium induce nucleotide imbalance and DNA damage responses, as well as impair the stability and activity of proteins which utilize [4Fe-4S] iron-sulfur clusters as cofactors. We identify a window of therapeutic opportunity upon riboflavin starvation or chemical riboflavin metabolism perturbation and demonstrate that this strongly synergizes with BCL-2 inhibition. Our work identifies riboflavin as a critical metabolic dependency in leukemia, with functions beyond energy production.

Identifiers

PMID40666848
PMCPMC12262817

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.